Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Pan Thin"'
Autor:
Vishnu Murthy, Emmanuel Appiah-Kubi, Kathleen Nguyen, Pan Thin, Masatoshi Hotta, John Shen, Alexandra Drakaki, Matthew Rettig, Andrei Gafita, Jeremie Calais, Ida Sonni
Publikováno v:
European Journal of Hybrid Imaging, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Purpose To evaluate whether quantitative whole-body (WB) PSMA-PET metrics under long-term androgen deprivation therapy (ADT) and/or androgen receptor signaling inhibitors (ARSi) are associated with PSA progression. Methods Patients who under
Externí odkaz:
https://doaj.org/article/50a32eb3847a4d65845ef2925ba1835b
Autor:
Lisa M. Gudenkauf, Melody N. Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I. Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R. Armstrong, Khaled Komrokji, Laura B. Oswald, Heather S.L. Jim, Ghassan El-Haddad, Wolfgang P. Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S. Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa, Brian D. Gonzalez
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol 64, iss 6
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc28323208a7a53159ef5fe209a12c7c
https://escholarship.org/uc/item/17m8q3sk
https://escholarship.org/uc/item/17m8q3sk
Autor:
Michael L. Steinberg, Kathleen Nguyen, Vinayak Muralidhar, Neil R. Parikh, Vincent Lok, Ting Martin Ma, Ida Sonni, Andrei Gafita, Pan Thin, David Elashoff, Johannes Czernin, Ricky Savjani, Matthew Rettig, Jesus E. Juarez, Jie Deng, Tristan Grogan, David Shabsovich, Amar U. Kishan, Patrick A. Kupelian, David D. Yang, Jeremie Calais, Nicholas G. Nickols, Carissa Chu, Felix Y. Feng, Wesley R Armstrong, Robert E. Reiter
Publikováno v:
Eur Urol Oncol
European urology oncology, vol 5, iss 1
European urology oncology, vol 5, iss 1
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is an emerging imaging modality with greater sensitivity and specificity over conventional imaging for prostate cancer (PCa) staging. Using data fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2641c06c641ca2b0573c6a4e1e6db325
https://doi.org/10.1016/j.euo.2021.01.006
https://doi.org/10.1016/j.euo.2021.01.006
Autor:
Lisa M. Gudenkauf, Melody Chavez, Melinda Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha Hoogland, Kathleen Nguyen, Laura B. Oswald, Heather S.L. Jim, Ghassan El-Haddad, Wolfgang Peter Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa, Brian D. Gonzalez
Publikováno v:
Journal of Clinical Oncology. 41:130-130
130 Background: The field of targeted radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first lutetium-177-PSMA-ligand. Commonly used patient-reported outcome (PRO) measures were originally designe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f74deee662995a2087e05072b1488534
https://doi.org/10.1200/jco.2023.41.6_suppl.130
https://doi.org/10.1200/jco.2023.41.6_suppl.130
Autor:
Wolfgang P. Fendler, Shadfar Bahri, David Ranganathan, Jeannine Gartmann, Johannes Czernin, Jeremie Calais, Rouzbeh Esfandiari, Martin Allen-Auerbach, Pan Thin, Beilei He, Kathleen Nguyen, Linda Gardner, Wesley R Armstrong, Andrew Quon, Pawan Gupta, Ken Herrmann, Magnus Dahlbom, Ebrahim S. Delpassand, Matthias Eiber
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol 62, iss 10
The purpose of this analysis was to report the safety evaluation of 177Lu-PSMA-617 derived from the cohort of 64 patients exposed to 177Lu-PSMA-617 in the RESIST-PC trial NCT03042312. Methods: RESIST-PC was a prospective multicenter phase 2 trial. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f93c9519090ec3e7cb8a41201dd19de
https://escholarship.org/uc/item/3n3680n9
https://escholarship.org/uc/item/3n3680n9
Autor:
Jeremie, Calais, Johannes, Czernin, Pan, Thin, Jeannine, Gartmann, Kathleen, Nguyen, Wesley R, Armstrong, Martin, Allen-Auerbach, Andrew, Quon, Shadfar, Bahri, Pawan, Gupta, Linda, Gardner, Magnus, Dahlbom, Beilei, He, Rouzbeh, Esfandiari, David, Ranganathan, Ken, Herrmann, Matthias, Eiber, Wolfgang P, Fendler, Ebrahim, Delpassand
Publikováno v:
J Nucl Med
The purpose of this analysis was to report the safety evaluation of (177)Lu-PSMA-617 derived from the cohort of 64 patients exposed to (177)Lu-PSMA-617 in the RESIST-PC trial NCT03042312. Methods: RESIST-PC was a prospective multicenter phase 2 trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::da29e7b8ea8c11e92000fb2d99262636
https://pubmed.ncbi.nlm.nih.gov/34272322
https://pubmed.ncbi.nlm.nih.gov/34272322
Autor:
Andrei, Gafita, Jeremie, Calais, Tristan R, Grogan, Boris, Hadaschik, Hui, Wang, Manuel, Weber, Shahneen, Sandhu, Clemens, Kratochwil, Rouzbeh, Esfandiari, Robert, Tauber, Anna, Zeldin, Hendrik, Rathke, Wesley R, Armstrong, Andrew, Robertson, Pan, Thin, Calogero, D'Alessandria, Matthew B, Rettig, Ebrahim S, Delpassand, Uwe, Haberkorn, David, Elashoff, Ken, Herrmann, Johannes, Czernin, Michael S, Hofman, Wolfgang P, Fendler, Matthias, Eiber
Publikováno v:
The Lancet. Oncology. 22(8)
Lutetium-177 (In this multicentre, retrospective study, we screened patients with mCRPC who had receivedBetween April 23, 2019, and Jan 13, 2020, 414 patients were screened; 270 (65%) of whom were eligible and were divided into development (n=196) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::110ef6b3937283abc7770650d98021e7
https://pubmed.ncbi.nlm.nih.gov/34592186
https://pubmed.ncbi.nlm.nih.gov/34592186
Autor:
Kathleen Nguyen, Jeannine Gartmann, Ebrahim S. Delpassand, Ken Herrmann, Roger Slavik, Martin Allen-Auerbach, Rouzbeh Esfandiari, David Ranganathan, Jeremie Calais, Linda Gardner, Vincent Lok, Shadfar Bahri, Magnus Dahlbom, Pan Thin, Johannes Czernin, Andrei Gafita, Pawan Gupta, Wolfgang P. Fendler, Laura Gosa, Wesley R Armstrong, Tristan Grogan, Matthias Eiber, Andrew Quon
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol 62, iss 10
J Nucl Med
J Nucl Med
The objective of this study was to determine prospectively the efficacy profile of 2 activity regimens of (177)Lu-PSMA therapy in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC): 6.0 vs. 7.4 GBq. Methods: RESIST-PC (NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354aa7aca16d8b533d44dfa8ed3839ad
https://pubmed.ncbi.nlm.nih.gov/34353872
https://pubmed.ncbi.nlm.nih.gov/34353872
Autor:
Andrei Gafita, Jeremie Calais, Tristan R. Grogan, Anna Zeldin, Boris Hadaschik, Wang Hui, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Hendrik Rathke, Wesley R. Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B. Rettig, Ebrahim S. Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Prof Michael S. Hofman, Wolfgang P. Fendler, Matthias Eiber
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::656b02739bf59b8ea54c514d4a250a39
https://doi.org/10.2139/ssrn.3798566
https://doi.org/10.2139/ssrn.3798566
Autor:
Clemens Kratochwil, Ken Herrmann, Andrew Robertson, Manuel Weber, Uwe Haberkorn, Ebrahim S. Delpassand, Rouzbeh Esfandiari, Pan Thin, Jeremie Calais, Hui Wang, Andrei Gafita, David Elashoff, Calogero D'Alessandria, Wesley R Armstrong, Tristan Grogan, Boris Hadaschik, Anna Zeldin, Robert Tauber, Johannes Czernin, Hendrik Rathke, Wolfgang P. Fendler, Matthias Eiber, Shahneen Sandhu, Matthew Rettig, Michael S Hofman
BACKGROUND: Lutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177Lu-PSMA to enhance its clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189814217b55251a7220b725a87462c9
https://mediatum.ub.tum.de/doc/1638543/document.pdf
https://mediatum.ub.tum.de/doc/1638543/document.pdf